Johanna Hynninen
Johanna Hynninen
Turku University Hospital, University of Turku
Verified email at utu.fi
Title
Cited by
Cited by
Year
A prospective comparison of integrated FDG-PET/contrast-enhanced CT and contrast-enhanced CT for pretreatment imaging of advanced epithelial ovarian cancer
J Hynninen, J Kemppainen, M Lavonius, J Virtanen, J Matomäki, S Oksa, ...
Gynecologic oncology 131 (2), 389-394, 2013
922013
FDG PET/CT in staging of advanced epithelial ovarian cancer: frequency of supradiaphragmatic lymph node metastasis challenges the traditional pattern of disease spread
J Hynninen, A Auranen, O Carpén, K Dean, M Seppänen, J Kemppainen, ...
Gynecologic oncology 126 (1), 64-68, 2012
822012
Is perioperative visual estimation of intra-abdominal tumor spread reliable in ovarian cancer surgery after neoadjuvant chemotherapy?
J Hynninen, M Lavonius, S Oksa, S Grénman, O Carpén, A Auranen
Gynecologic oncology 128 (2), 229-232, 2013
802013
Serum HE4 and CA125 as predictors of response and outcome during neoadjuvant chemotherapy of advanced high-grade serous ovarian cancer
T Vallius, J Hynninen, A Auranen, O Carpén, J Matomäki, S Oksa, ...
Tumor Biology 35 (12), 12389-12395, 2014
592014
A functional homologous recombination assay predicts primary chemotherapy response and long-term survival in ovarian cancer patients
M Tumiati, S Hietanen, J Hynninen, E Pietilä, A Färkkilä, K Kaipio, ...
Clinical Cancer Research 24 (18), 4482-4493, 2018
482018
18F-FDG-PET/CT can identify histopathological non-responders to platinum-based neoadjuvant chemotherapy in advanced epithelial ovarian cancer
T Vallius, A Peter, A Auranen, O Carpén, J Kemppainen, J Matomäki, ...
Gynecologic oncology 140 (1), 29-35, 2016
382016
Serum HE4 profile during primary chemotherapy of epithelial ovarian cancer
J Hynninen, A Auranen, K Dean, M Lavonius, O Carpen, A Perheentupa, ...
International Journal of Gynecologic Cancer 21 (9), 2011
352011
Identification of prognostic groups in high-grade serous ovarian cancer treated with platinum–taxane chemotherapy
P Chen, K Huhtinen, K Kaipio, P Mikkonen, V Aittomäki, R Lindell, ...
Cancer research 75 (15), 2987-2998, 2015
302015
Roles of human epididymis protein 4, carbohydrate antigen 125, inhibin B and anti-Müllerian hormone in the differential diagnosis and follow-up of ovarian granulosa cell tumors
UM Haltia, M Hallamaa, J Tapper, J Hynninen, H Alfthan, B Kalra, ...
Gynecologic oncology 144 (1), 83-89, 2017
252017
Mathematical modeling predicts response to chemotherapy and drug combinations in ovarian cancer
E Kozłowska, A Färkkilä, T Vallius, O Carpén, J Kemppainen, S Grénman, ...
Cancer research 78 (14), 4036-4044, 2018
232018
PET/CT for evaluation of ovarian cancer
J Kemppainen, J Hynninen, J Virtanen, M Seppänen
Seminars in nuclear medicine 49 (6), 484-492, 2019
212019
Genetically defined syngeneic mouse models of ovarian cancer as tools for the discovery of combination immunotherapy
S Iyer, S Zhang, S Yucel, H Horn, SG Smith, F Reinhardt, E Hoefsmit, ...
Cancer Discovery 11 (2), 384-407, 2021
202021
Postoperative human epididymis protein 4 predicts primary therapy outcome in advanced epithelial ovarian cancer
T Vallius, J Hynninen, A Auranen, J Matomäki, S Oksa, P Roering, ...
Tumor Biology 39 (2), 1010428317691189, 2017
192017
REG4 is highly expressed in mucinous ovarian cancer: a potential novel serum biomarker
L Lehtinen, P Vesterkvist, P Roering, T Korpela, L Hattara, K Kaipio, ...
PLoS One 11 (3), e0151590, 2016
182016
ALDH1A1‐related stemness in high‐grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR‐PI3K/aurora kinase inhibitors
K Kaipio, P Chen, P Roering, K Huhtinen, P Mikkonen, P Östling, ...
The Journal of pathology 250 (2), 159-169, 2020
172020
18 F-FDG-PET/CT based total metabolic tumor volume change during neoadjuvant chemotherapy predicts outcome in advanced epithelial ovarian cancer
T Vallius, J Hynninen, J Kemppainen, V Alves, K Auranen, J Matomäki, ...
European journal of nuclear medicine and molecular imaging 45 (7), 1224-1232, 2018
172018
A nanoparticle-lectin immunoassay improves discrimination of serum CA125 from malignant and benign sources
K Gidwani, K Huhtinen, H Kekki, S van Vliet, J Hynninen, N Koivuviita, ...
Clinical chemistry 62 (10), 1390-1400, 2016
152016
Europium nanoparticle-based sialyl-tn monoclonal antibody discriminates epithelial ovarian Cancer–Associated CA125 from benign sources
K Gidwani, N Nadeem, K Huhtinen, H Kekki, T Heinosalo, J Hynninen, ...
Journal of Applied Laboratory Medicine 4 (3), 299-310, 2019
112019
Prospective longitudinal ctDNA workflow reveals clinically actionable alterations in ovarian cancer
J Oikkonen, K Zhang, L Salminen, I Schulman, K Lavikka, N Andersson, ...
JCO Precision Oncology 3, 1-12, 2019
112019
A longitudinal analysis of CA125 glycoforms in the monitoring and follow up of high grade serous ovarian cancer
L Salminen, N Nadeem, S Jain, S Grènman, O Carpén, S Hietanen, ...
Gynecologic oncology 156 (3), 689-694, 2020
102020
The system can't perform the operation now. Try again later.
Articles 1–20